Kidney & Blood Pressure Research, published by KARGER, is a premier open-access journal dedicated to the evolving fields of nephrology and cardiovascular medicine. Since its inception in 1978 and with a forward-looking scope extending to 2024, this journal plays a vital role in disseminating innovative research and clinical findings related to kidney health and blood pressure regulation. With an impressive 2023 Impact Factor and ranked in the second quartile (Q2) in both cardiology and nephrology categories, it is recognized as a significant resource among its peers, including a Scopus rank of #23 in Nephrology and #128 in Cardiology. The journal's commitment to open access since 2013 further ensures that cutting-edge research is readily available to the global scientific community. Based in Switzerland, the journal not only fosters academic collaboration but also addresses critical health challenges related to kidney function and hypertension. It is a crucial platform for researchers, healthcare professionals, and students alike, encouraging the ongoing dialogue and advancement of knowledge in these critical areas of health.

Journal fur Hypertonie is a leading academic journal published by KRAUSE & PACHERNEGG GMBH, dedicated to the critical field of hypertension research. Since its inception in 1998, the journal has served as a vital platform for disseminating pioneering studies and advancements in the diagnosis, treatment, and management of hypertension. Although its Scopus coverage was discontinued in 2016, the journal continues to hold significance within the academic community, evidenced by its ranking of #98 out of 124 in Internal Medicine, placing it in the 21st percentile. This reflects its targeted impact and relevance in the evolving landscape of cardiovascular research. With no Open Access options, the journal remains a specialized resource indispensable for researchers, healthcare professionals, and students focused on enhancing their understanding and clinical practices related to hypertension. The journal's address is MOZARTGASSE 10, GABLITZ 3003, AUSTRIA.

The Egyptian Heart Journal, published by Springer, is a premier open-access journal dedicated to advancing the field of cardiology and cardiovascular medicine. As of 2023, it holds a Q3 classification within the category, showcasing its growing influence within the research community, and ranks 241 out of 387 in Scopus, reflecting a 37th percentile position. With an E-ISSN of 2090-911X, this journal has been open access since 2011, making it easily accessible to researchers, practitioners, and students alike. The journal aims to disseminate high-quality research articles, reviews, and case studies that contribute to the understanding and treatment of cardiovascular diseases. With its focus on innovative and practical solutions in cardiology, the Egyptian Heart Journal plays a critical role in shaping current and future cardiovascular research. Its global outreach and commitment to open access ensure that vital information is available to a wide audience, enhancing both scholarly discourse and clinical practice in the evolving landscape of cardiovascular medicine.

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.

Ophthalmology Glaucoma is a premier academic journal dedicated to advancing the understanding and management of glaucoma, a leading cause of irreversible blindness worldwide. Published by Elsevier, this journal covers a broad spectrum of topics within the field of ophthalmology, providing a platform for groundbreaking research and clinical insights. With an impressive impact factor that places it in the Q1 category of ophthalmology journals, and a commendable Scopus ranking of 29 out of 137, Ophthalmology Glaucoma is recognized for its rigorous peer-review process and high-quality publications. Since its inception in 2018, the journal has focused on disseminating innovative findings and treatment modalities to enhance patient care and outcomes. Researchers, clinicians, and students are encouraged to explore the Open Access options available, promoting wider accessibility to critical scientific knowledge. By staying at the forefront of ophthalmic research, Ophthalmology Glaucoma plays an essential role in shaping practices and policies that improve eye health globally.

HYPERTENSION, published by Lippincott Williams & Wilkins, is a preeminent journal in the field of cardiovascular medicine, focusing on the latest research, therapies, and clinical practices related to hypertension and its associated disorders. With a distinguished Q1 ranking in Internal Medicine and a commendable Scopus rank of #12 out of 167 in its category, it occupies a vital position within the academic community, appealing to researchers, clinicians, and educators alike. The journal has been disseminating impactful findings since 1979 and continues to influence the discourse on hypertension through rigorous peer-reviewed articles, reviews, and studies designed to elevate understanding and treatment of this prevalent condition. HYPERTENSION remains an essential resource for professionals keen on advancing their knowledge in this critical area of medicine, fostering innovations that ultimately improve patient care.

HEART AND VESSELS is a prominent peer-reviewed journal published by SPRINGER, dedicated to advancing the fields of cardiology and cardiovascular medicine. With its ISSN 0910-8327 and E-ISSN 1615-2573, this esteemed journal encompasses a broad range of topics pertinent to heart health, vascular function, and associated therapies, making it an essential resource for researchers, clinicians, and healthcare professionals alike. Based in Japan and operating since 1985, HEART AND VESSELS has consistently maintained a Q2 ranking in the 2023 category quartiles, highlighting its relevance and impact in the cardio domain. Although it does not offer open access, the journal ensures high-quality publications that contribute significantly to the academic and clinical understanding of cardiovascular health. With over three decades of continuous scholarly contribution, HEART AND VESSELS serves as a vital platform for disseminating cutting-edge research and fostering innovative practices in the management of cardiovascular diseases.

Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

AKTUELLE RHEUMATOLOGIE is a prominent German journal published by GEORG THIEME VERLAG KG, dedicated to advancing the field of rheumatology. Since its inception in 1978, this peer-reviewed journal has been a vital resource for professionals, researchers, and students engaged in the study and treatment of rheumatic diseases. With an ISSN of 0341-051X and an E-ISSN of 1438-9940, the journal provides a platform for sharing groundbreaking research, clinical studies, and reviews. Although classified in the fourth quartile (Q4) of rheumatology journals and ranked 67 out of 73 in its category according to Scopus, AKTUELLE RHEUMATOLOGIE continues to contribute to the discourse in rheumatology. Its comprehensive coverage of recent advancements and innovative approaches makes it an essential publication for anyone interested in the latest developments in the field.